Klastersky J, Zinner S H
Rev Infect Dis. 1982 Mar-Apr;4(2):294-301. doi: 10.1093/clinids/4.2.294.
In vitro synergy (or at least an additive effect between antibiotics in vitro) is likely to have clinical significance. Data in the literature strongly suggest that, in patients who lack the natural mechanisms of defense against infection, better clinical results can be achieved by treatment with two drugs to which the pathogenic organism is sensitive rather than only one. Moreover, there is some evidence that the use of antibiotic combinations found to be synergistic in vitro is associated with a better clinical outcome in patients with decreased mechanisms of defense against infection, especially neutropenia. The use of synergistic drug combinations should be continued as empirical therapy in severely neutropenic or otherwise compromised patients, especially in those with malignant tumors.
体外协同作用(或至少抗生素之间的体外相加作用)可能具有临床意义。文献数据有力地表明,在缺乏抗感染天然防御机制的患者中,使用两种病原菌敏感的药物进行治疗比仅使用一种药物能取得更好的临床效果。此外,有证据表明,在抗感染防御机制降低的患者,尤其是中性粒细胞减少症患者中,使用体外发现具有协同作用的抗生素组合与更好的临床结局相关。对于严重中性粒细胞减少或其他免疫功能受损的患者,尤其是患有恶性肿瘤的患者,应继续使用协同药物组合作为经验性治疗。